Tumor Antigen Expression in Ovarian Tissue
Author Information
Author(s): AM Gillespie, S Rodgers, AP Wilson, J Tidy, RC Rees, RE Coleman, AK Murray
Primary Institution: University of Sheffield
Hypothesis
Are ovarian cancer patients suitable for MAGE-peptide vaccine-based immunotherapy?
Conclusion
The study suggests that serous cystadenocarcinomas may be suitable for MAGE-1 peptide immunotherapy.
Supporting Evidence
- 1 out of 16 normal ovarian tissue specimens expressed MAGE-1.
- 11 out of 25 benign lesions expressed MAGE-1.
- 15 out of 27 malignant specimens expressed MAGE-1, including 10 out of 14 serous cystadenocarcinomas.
- Statistical significance was found in the expression of MAGE-1 in premenopausal women compared to postmenopausal women.
Takeaway
This study looked at ovarian tissue to see if certain genes related to cancer are present, which could help in developing new treatments.
Methodology
The study used reverse transcription polymerase chain reaction (RT-PCR) to assess gene expression in ovarian tissue samples.
Limitations
The study does not establish a direct relationship between MAGE gene expression and patient outcomes due to insufficient follow-up.
Participant Demographics
The study included women undergoing surgical management of gynecological conditions, with a focus on premenopausal and postmenopausal status.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website